Sun Pharma, Cipla, other pharma stocks in focus as Trump unveils 100%, 200% tariffs on generic drugs from 2028
Awaiting price reaction for this filing.
US President Donald Trump announced phased tariffs on generic drugs imported into the US, starting with no duties for two years, followed by a 100 percent tariff from August 1, 2028 and 200 percent by August 1, 2029. The move, aimed at pushing pharmaceutical companies to set up manufacturing in the US, directly impacts Indian drugmakers including Sun Pharma, Cipla, Aurobindo Pharma, Dr Reddy's, Lupin, Zydus Lifesciences, Alkem Laboratories, Torrent Pharmaceuticals, Biocon and Senores Pharmaceuticals. Companies with existing US manufacturing footprints such as Aurobindo Pharma are better positioned, while those dependent on Indian facilities face greater long-term pressure on US generic export economics.